FDA Approves Monthly Injectable Schizophrenia Treatment Weltruza

The FDA has approved Weltruza (olanzapine), a new treatment for adult schizophrenia, as the first once-monthly subcutaneous injection. Clinical trials showed improved symptoms, reduced illness severity, and enhanced personal and social functioning. This approval offers a significant new option for patients, potentially improving adherence and quality of life for those managing schizophrenia.